Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Debate 42A Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 42B Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 43A Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 43B Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 44A What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 44B What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 45A Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 45B Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 46A What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 46B What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 47A Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Debate 47B Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Debate 43B - Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
No
from Section V - Cervical Cancer
Published online by Cambridge University Press: 20 July 2023
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Debate 42A Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 42B Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 43A Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 43B Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 44A What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 44B What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 45A Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 45B Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 46A What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 46B What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 47A Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Debate 47B Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Summary
Although radical hysterectomy or radical trachelectomy with lymph node assessment are both considered a gold standard treatment for patients with cervical cancer stages IA2 and IB1, radical procedures (parametrectomy) are associated with an increased risk of morbidity and inferior quality of life as well as adverse obstetrical outcomes for radical trachelectomy. Moreover, prior studies demonstrated that in patients with favorable factors, such as: tumor size ≤2 cm, depth of stromal invasion <10 mm, and the absence of lymphovascular space, and negative pelvic nodes the risk of parametrial involvement is below 1%. The mounting evidence from retrospective and prospective studies (ConCerv trial) suggest that in those with a low risk of parametrial involvement simple surgery (conization, trachelectomy or hysterectomy) with lymph node assessment might be a safe alternative to the radical surgery (parametrectomy). It is expected that the results of two large prospective trials: GOG 278 and SHAPE will add to this debate in favor of “simple” surgery with lymph node assessment.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 262 - 264Publisher: Cambridge University PressPrint publication year: 2023